Skip to main content

Table 1 Characteristics of 2888 patients in the Chicago multiethnic epidemiologic cohort of breast cancer study*

From: Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients

Characteristic

White

Black

Asian

Hispanic

P

N

1575

1106

126

81

 

Age at diagnosis, n (%)

 < 40

147 (9.3)

86 (7.8)

17 (13.5)

15 (18.5)

< 0.001

 40–49

432 (27.4)

191 (17.3)

48 (38.1)

23 (28.4)

 

 -59

463 (29.4)

262 (23.7)

25 (19.8)

14 (17.3)

 

 60–69

334 (21.2)

262 (23.7)

25 (19.8)

15 (18.5)

 

 70+

199 (12.6)

305 (27.6)

11 (8.7)

14 (17.3)

 

Mean (SD)

54.7 (12.3)

59.6 (13.9)

51.1 (12.5)

53.8 (14.5)

< 0.001

Smoking status, n (%)

 Never smoker

968 (63.5)

597 (55.2)

105 (90.5)

48 (62.3)

< 0.001

 Previous smoker

416 (27.3)

313 (29.0)

9 (7.8)

23 (29.9)

 

 Current smoker

140 (9.2)

171 (15.8)

2 (1.7)

6 (7.8)

 

Insurance status, n (%)

 No

7 (0.4)

2 (0.2)

0 (0.0)

1 (1.2)

< 0.001

 Private

1149 (73.0)

433 (39.2)

95 (75.4)

52 (64.2)

 

 Medicaid

37 (2.3)

166 (15.0)

4 (3.2)

5 (6.2)

 

 Medicare

346 (22.0)

476 (43.0)

25 (19.8)

22 (27.2)

 

 Other/unknown

36 (2.3)

29 (2.6)

2 (1.6)

1 (1.2)

 

Carlson comorbidity index, n (%)

 0

1318 (83.7)

762 (68.9)

108 (85.7)

63 (77.8)

< 0.001

 1

114 (7.2)

134 (12.1)

11 (8.7)

6 (7.4)

 

 2

115 (7.3)

132 (11.9)

4 (3.2)

11 (13.6)

 

 3

28 (1.8)

78 (7.1)

3 (2.4)

1 (1.2)

 

Tumor stage, n (%)

 0

263 (16.7)

195 (17.6)

24 (19.0)

9 (11.1)

0.097

 1

628 (39.9)

372 (33.6)

42 (33.3)

30 (37.0)

 

 2

505 (32.1)

391 (35.4)

43 (34.1)

30 (37.0)

 

 3

179 (11.4)

148 (13.4)

17 (13.5)

12 (14.8)

 

Estrogen receptor, n (%)

 Negative

284 (19.2)

307 (30.3)

16 (13.6)

20 (25.3)

< 0.001

 Positive

1193 (80.8)

706 (69.7)

102 (86.4)

59 (74.7)

 

Progesterone receptor, n (%)

 Negative

458 (31.1)

436 (43.0)

29 (24.6)

26 (32.9)

< 0.001

 Positive

1016 (68.9)

578 (57.0)

89 (75.4)

53 (67.1)

 

Her2 status, n (%)

 Negative

1051 (83.7)

734 (83.1)

76 (74.5)

62 (87.3)

0.084

 Positive

204 (16.3)

149 (16.9)

26 (25.5)

9 (12.7)

 

Molecular subtype, n (%)

 ER/PR+, her2-

884 (70.4)

511 (57.9)

68 (66.7)

49 (69.0)

< 0.001

 ER/PR+, her2+

128 (10.2)

90 (10.2)

18 (17.6)

6 (8.5)

 

 ER/PR-, her2+

76 (6.1)

58 (6.6)

8 (7.8)

3 (4.2)

 

 Triple negative

167 (13.3)

223 (25.3)

8 (7.8)

13 (18.3)

 

Histologic grade, n (%)

 1

230 (15.6)

134 (12.8)

21 (17.8)

9 (11.5)

< 0.001

 2

742 (50.3)

456 (43.6)

61 (51.7)

41 (52.6)

 

 3

504 (34.1)

456 (43.6)

36 (30.5)

28 (35.9)

 

Type of surgery, n (%)

 No surgery

13 (0.8)

12 (1.1)

0 (0.0)

0 (0.0)

< 0.001

 Breast conserving surgery

913 (58.7)

683 (65.1)

62 (49.6)

45 (57.7)

 

 Mastectomy

629 (40.5)

354 (33.8)

63 (50.4)

33 (42.3)

 

Chemotherapy, n (%)

 No

881 (55.9)

586 (53.0)

71 (56.3)

39 (48.1)

0.28

 Yes

694 (44.1)

520 (47.0)

55 (43.7)

42 (51.9)

 

Hormonal therapy, n (%)

 No

495 (31.4)

462 (41.8)

27 (21.4)

28 (34.6)

< 0.001

 Yes

1080 (68.6)

644 (58.2)

99 (78.6)

53 (65.4)

 

Radiotherapy, n (%)

 No

657 (41.7)

437 (39.5)

63 (50.0)

28 (34.6)

0.074

 Yes

918 (58.3)

669 (60.5)

63 (50.0)

53 (65.4)

 

BMI at baseline, n (%)

 Underweight

19 (1.4)

4 (0.5)

2 (2.0)

0 (0.0)

< 0.001

 Normal weight

548 (41.6)

143 (16.9)

58 (58.6)

13 (22.4)

 

 Overweight

388 (29.5)

261 (30.9)

28 (28.3)

30 (51.7)

 

 Obese

362 (27.5)

438 (51.8)

11 (11.1)

15 (25.9)

 

Mean (SD)

27.5 (6.4)

31.5 (7.3)

24.6 (4.3)

28.7 (6.2)

< 0.001

  1. *Number (%) are presented if not otherwise specified and numbers are not added up to total due to missing data. In particular, Her2 data were collected for few patients with stage 0 tumors
  2. Abbreviation: BMI body mass index, SD standard deviation, ER estrogen receptor, PR progesterone receptor